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Article
Recent Progress in Osteocyte Research
Paola Divieti Pajevic
Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
The last decade has seen an exponential increase in our understanding of osteocytes function and biology. These cells, once con-
sidered inert by-standers trapped into the mineralized bone, has now risen to be key regulators of skeletal metabolism, mineral 
homeostasis, and hematopoiesis. As tools and techniques to study osteocytes improved and expanded, it has become evident that 
there is more to these cells than initially thought. Osteocytes are now recognized not only as the key responders to mechanical 
forces but also as orchestrators of bone remodeling and mineral homeostasis. These cells are the primary source of several impor-
tant proteins, such as sclerostin and fibroblast growth factor 23, that are currently target as novel therapies for bone loss (as the 
case for antisclerostin antibodies) or phosphate disorders. Better understanding of the intricate cellular and molecular mecha-
nisms that govern osteocyte biology will open new avenue of research and ultimately indentify novel therapeutics to treat bone 
and mineral disorders. This review summarizes novel findings and discusses future avenues of research.
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INTRODUCTION
Our understanding of the function of osteocytes has expanded 
dramatically over the last decade primarily due to the identifi-
cation of osteocytes specific markers, such as dentin matrix 
protein 1 (DMP1) and SOST/sclerostin, that has allowed, for 
the first time a closer look at the biology of these cells. Osteo-
cytes, the cells deeply entrapped into the mineralized matrix, 
have emerged as key regulators not only of skeletal and min-
eral homeostasis, but also hematopoiesis. This review will 
summarize novel findings in osteocyte biology and future ave-
nues of research.
THE OSTEOCYTES
Osteocytes are postmitotic, terminally differentiated osteo-
blasts that during the process of matrix mineralization remain 
entrapped in the mineralizing matrix that they are actively 
synthesizing. They reside both in the mineralized matrix and 
in the newly formed osteoid. Earlier work of Gaillard et al. [1]     
and Rutishauser and Majno [2], described two stages into the 
life of an osteocyte; an early stage (young osteocyte) in which 
the cell is smaller in size, reside into the osteoid and do not 
express alkaline phosphatase and a late stage (mature osteo-
cyte) in which the larger cell re-express alkaline phosphatase 
and is deeply embedded in the mineralized bone. The larger 
cell will then degenerate and leave an empty lacuna [1]. This 
classification has been recently revised to include an addition-
al stage of differentiation: according to their spatial localiza-
tion and gene expression, these cells are now divided into os-
teoid, mineralizing, and the mature osteocytes [3]. The oste-
oid, or nascent osteocyte is characterized by a relative proxim-
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ity to the endosteal (and possibly periostal) surface and the ex-
pression of transcripts such as E11/gp38/podoplain [4], matrix 
extracellular phosphoglycoprotein (MEPE) and phosphate-
regulating gene with homologies to endopeptidases on the X 
chromosome (Phex). This cell, opposite to the more mature 
osteocyte, is negative for sclerostin and fibroblast growth fac-
tor (FGF)-23 expression but does express DMP1, as elegantly 
demonstrated by Kalajzic et al. [5] in a recent review. It is not 
clear, however, if osteoid, mineralizing and mature osteocytes 
exert different biological functions or if they all work as 
mechanosensor and skeletal regulators. Indeed recent studies 
suggest that cortical and trabecular osteocytes might have dis-
tinct roles with the former being the sensor of load while the 
latter being the controller of bone metabolism. Windahl et al. 
[6], for example, reported that estrogen receptor-α ablation in 
osteocytes differentially affects trabecular and cortical bone 
compartments in males mice.
  Marotti et al. [7] and Palumbo et al. [8,9] have extensively 
described the morphological changes that accompany the 
transformation from a motile osteoblast into an entombed os-
teocyte. They demonstrate, by histological analysis of new-
born rabbit bones, that the formation of osteocyte cytoplasmic 
processes is asynchronous and asymmetrical and precede the 
mineralization of the organic matrix. Moreover, osteocytes are 
evolutionary highly conserved and the organized structure of 
these cells within a mineralized matrix is present in bone spec-
imens from Tyrannosaurus rex, dating back more than 80 mil-
lion of years ago, clearly indicating an important role for these 
cells in skeletal metabolism [10].
  Osteocytes communicate with each other and with cells at 
the endosteal and periosteal surface through an extensive and 
intricate system of canaliculi. These cells are also in close 
proximity of capillary and vessels, raising the hypothesis that 
osteocytes might function as an endocrine organ and directly 
secrete proteins, such as FGF-23, Phex, or sclerostin into the 
circulation [11]. Moreover, the osteocytic network, with its 
extensive system, is an ideal structure to sense mechanical 
loading and control mineral homeostasis. It has been postulat-
ed that osteocytes can send signals for both bone resorption 
and formation and thus orchestrate a proper cycle of remodel-
ing, as discussed in details below.
OSTEOCYTE FUNCTIONS: 
MECHANOTRANSDUCTION
What are the functions of an osteocyte? It has been recognized 
for over 30 years that osteocytes are mechanosensor of bone. 
They are indeed the cells capable of sensing mechanical forces 
applied to the skeleton and transform these forces into biologi-
cal stimuli. It is now widely accepted that the cell perceives 
forces in the form of shear stress created by the flow of fluid 
inside the lacuna-canalicular network. It has been proposed 
that the flow derives from both the compression induced by 
loading and the extravascular pressure. Efforts to physically 
measure and quantify this flow are currently ongoing and re-
cent reports suggest that osteocytes are subjected to forces in 
the order of 5 Pa [12]. Although the theory that osteocytes are 
the mechanosensor of bone has been around for decades, the 
definite demonstration of this theory comes from work of Tat-
sumi et al. [13]. Using a mouse model of targeted osteocytes 
ablation, they demonstrated resistance to disuse induces bone 
loss highlighting the central role that osteocytes play in mech-
anosensation. How an osteocyte can sense the fluid flow in the 
lacuno-canalicular network is still not completely understood. 
Primary cilia have been described as important mechanosen-
sor and mice lacking Kif3a or ITF88 (polaris), both key com-
ponents of the cilia, in bone cells, display skeletal abnormali-
ties. Targeted ablation of Kif3a from osteoblasts, and conse-
quently from osteocytes, using the Col1α 2.3 promoter, affects 
skeletal anabolic responses to cyclic axial compression, sug-
gesting that primary cilia are needed for proper skeletal mech-
anosensory [14,15]. Similarly, mice with in which PDK1 is 
ablated in osteocytes, using the 10kb-DMP1 promoter have 
impaired anabolic response to mechanical loading, further 
supporting the importance of cilia in skeletal mechanosensa-
tion [16,17].
  Osteocytes responses to load, both in vivo and in vitro, include 
secretion of prostaglandin E2 and nitric oxide and the expression 
of several mechanosensitive transcripts such as DMP1, MEPE, 
and Phex [18,19]. Another osteocytic gene highly regulated by 
mechanical forces is SOST. SOST/sclerostin in suppressed dur-
ing load whereas it is increased during hindlimb unloading [20]. 
Moreover mice lacking SOST are resistant to disuse induced 
bone loss and antisclerostin antibodies can prevent bone loss as-
sociated with hindlimb unloading [21]. This demonstrates that 
osteocytes are key orchestrators not only of skeletal responses to 
loading but also to unloading, as occurs during paralysis, pro-
longed bed rest or space flight. Frost [22] postulated that osteo-
cytes are the mechanostat of bone, ascribing to these cells the 
role of driving skeletal adaptation to mechanical forces. Bone 
adapts its form to mechanical demands trough a mechanisms 
known as bone modeling. During modeling, bone resorption, Recent Progress in Osteocytes 
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driven by osteoclasts, and bone formation, osteoblasts-mediated, 
occurs on different surfaces of the skeleton such as the bone un-
dergoes reshaping to adapt to different loading conditions. Bone 
remodeling, on the other hand, is the continuous and spatially 
coupled, resorption and formation of the skeleton to preserve 
functional integrity. According to Frost [22], the mechanostat 
distinguishes between bone modeling (shape change) and re-
modeling (replacement only). Examples of bone adaptation to 
loading are evident in professional athletes, where the high load 
applied to the skeleton results in stronger and bigger bones, 
whereas in astronauts or in paralyzed patients there is severe 
bone loss due to unloading. As described above, compelling evi-
dences ascribe to sclerostin an important role in this disuse in-
duced bone loss.
BONE AND MINERAL HOMEOSTASIS
Osteocytes are not only the sensor of mechanical forces, they 
are also master controller of bone and mineral homeostasis. 
These cells are, postnatally, the main source sclerostin and re-
ceptor activation of nuclear factor-κB ligand (RANKL). 
Sclerostin, the product of the gene SOST, has emerged as a 
powerful inhibitor of bone formation. The protein binds to 
LRP5 and the related LRP6 and four receptors and block the 
canonical Wnt-ßcatenin signaling pathway. Lack (or mutation) 
of sclerostin induces sclerosteosis whereas its over expression 
causes severe osteopenia (for review on Wnts) [23]. Osteo-
cytes are also the main source of FGF-23, a key regulator, to-
gether with parathyroid hormone (PTH) of phosphate homeo-
stasis [24,25]. Thus, it is not surprising that genetic manipula-
tion of osteocytes induced both skeletal and mineral defects. 
Mice lacking RANKL in osteocytes have increased bone min-
eral density and reduced bone remodeling [26,27], as do mice 
lacking the receptor of PTH (PTH1R). Mice lacking Atg7, an 
autophagy gene, from osteocytes, display similar skeletal phe-
notype as aging mice, indicating that these cells are key regu-
lator of skeletal metabolism [28]. Both DMP1-null mice and 
individuals with inactivating mutation of this gene have rickets 
and osteomalacia and are hypophostatemic as a consequence of 
high levels of FGF-23 [29]. On the contrary, mice lacking 
FGF-23 are hyperphosphatemic, osteopenic, and dye prema-
turely. It has been reported that osteocytes are also the major 
source of insulin-like growth factor (IGF)-1 and IGF-1 pro-
duced by these cells is required for proper anabolic responses 
to mechanical loading. Deletion of IGF-1 in osteocytes, (using 
the DMP1-Cre promoter) impairs skeletal growth, have re-
duced periosteal circumference and have a blunted response to 
mechanical forces. When IGF-1 conditional KO mice were 
subjected to mechanical loading, there was a significant reduc-
tion in osteoblastic bone formation response, indicating that 
IGF-1 is an important determinant of both bone size and bone 
strength [30].
  Pioneering studies on osteocytes involving histological 
analysis of bone specimens raised the possibility that osteo-
cytes could reabsorb bone and directly contribute to mineral-
ion homeostasis. The finding that in various diseases (renal 
osteodystrophy, hyperparathyroidism, and immobilization) the 
size of the osteocytic lacunae was increased led to the hypoth-
esis that these cells were indeed capable of modifying the 
perilacunar mineralized matrix. This theory was quickly aban-
doned when isolated osteocytes failed to reabsorb bone is a 
classical osteoclast pit-forming assay and few decades later, 
the concept that osteocytes can indeed reabsorb their perilacu-
nal matrix has been revisited. The current osteocytic osteolysis 
concept, as proposed by Cullinane [31], suggests that osteo-
cytes do not remove substantial amount of bone (as osteo-
clast), but rather modify the matrix minerals in the perilacunar 
areas. This perilacunal remodeling is evident during continu-
ous infusion with PTH [32], treatment with prednisone [33] or 
during lactation [34]. As described above, osteocytes express 
receptor for PTH, a known regulator of calcium homeostasis, 
and they are the ideal candidates for systemic homeostasis 
regulation. Mice lacking the PTH1R specifically in osteocytes 
have indeed an impaired calcium homeostasis when subjected 
to a low calcium diet, indicating these cells also control calci-
um homeostasis [35]. Lastly, when the vitamin D receptor is 
ablated from osteocytes, the animals are unable to mobilize 
calcium from bone under a vitamin D stimulus, indicating that 
vitamin D signaling in osteocytes is critical for moving calci-
um from skeletal stores to the blood [36]. In light to recent re-
port indicating that osteocytes are the major source of RANKL 
and therefore bone remodeling [26,27], we can speculate that 
the calcemic effect of vitamin D on bone is via osteocyte-de-
rived RANKL although evidences for this pathway are still 
missing.
HEMATOPOIESIS
Hematopoiesis, the process that continuously gives rise blood 
cells, is tightly regulated not only by intrinsic factors but also 
by extrinsic clues derived from various cells within the bone 
marrow microenvironment. The bone marrow is indeed the pri-Pajevic PD
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mary site for hematopoiesis that is highly orchestrated by inter-
actions between the hematopoietic stem cells (HSCs) and their 
niches on the endosteal bone surface. The HSC niche consists 
of cells from the osteolineage, sinusoidal endothelial cells, 
mesenchymal stromal and stem cells, sympathetic neurons, and 
the extracellular matrix [37,38]. In these niches, the HSC un-
dergo self-renewal and/or differentiate into hematopoietic lin-
eage with cues from the niche-supporting cells, which provide 
structural as well as signaling support for the hematopoietic 
microenvironment. Osteoblasts have been shown as critical 
regulators of HSC maintenance, proliferation, and maturation 
[39,40] via various cell-surface proteins such as Notch1 ligand 
Jagged1 and via secreted cytokines such as CXCL12. Osteo-
blasts also provide a niche for B-lymphopoiesis in part via in-
terleukin-7 expression through Gsα-signaling [41]. Hypoxic 
osteoblasts are also a major producer of erythropoietin through 
which they regulate erythropoiesis [42]. Moreover, osteoclasts 
has been shown to be potential HSC regulators through degra-
dation of endosteal components and promotion of mobilization 
of HSCs [43]. In contrast, the role of osteocytes in HSC and 
progenitor regulation, and hence hematopoiesis, has remained 
completely unexplored despite the fact that these cells com-
prise 90% to 95% of all bone cells in the adult skeleton and 
they produce an extensive canalicular network that reaches the 
endosteal bone surface, a preferred site for the HSC niche. Os-
teoblasts and osteocytes express several G-protein coupled re-
ceptor (GPCR) and signaling trough these receptor s has been 
shown to control the niche. Interestingly constitutive activation 
of the PTH/PTHrP receptor in osteoblasts increased the num-
bers of HSCs [39] whereas its expression in osteocytes does 
not [44], suggesting that cells early in the osteoblast lineage are 
critical for maintaining an intact HSC niche. To examine the 
role of osteocytes and GPCR signaling in regulation of hema-
topoiesis we recently generated mice lacking Gsα in osteocytes 
(Ocy-Gsα
KO). Surprisingly, ablation of Gsα from these cells in-
duces a marked neutrophilia, thrombocytopenia and spleno-
megaly. Ocy-Gsα
KO mice displayed a profound myeloprolifera-
tive phenotype characterized by a dramatic increase in myeloid 
cells in bone marrow, spleen, and peripheral blood and marked 
[45]. Using a novel ex vivo coculture system using osteocyte-
enriched bone explants we identified granulocyte colony-stim-
ulating factor as the principal cytokine regulating granulopoie-
sis in these mice. Interestingly, PTH1R signaling in osteocytes 
is not responsible for the myeloproliferative phenotype since 
mice lacking receptor expression in osteocytes (Ocy-PPR
KO) 
have normal hematopoiesis [45]. Moreover, the expression of 
SOST/sclerostin, a Wnt inhibitor and suppressor of osteoblast 
proliferation and functions, was increased significantly in these 
mice. Treatment with antisclerostin antibody partially restored 
the number of osteoblasts in Ocy-Gsα
KO mice without rescuing 
the bone marrow abnormalities demonstrating that the hemato-
poietic abnormalities present in these mice are independent on 
osteoblasts or increased SOST/sclerostin expression [45]. On 
the other hand, SOST/sclerostin can directly control the fate of 
B-cells, as recently reported [46]. Cain et al. [46] showed that 
SOST-/- mice, despite the high bone mass and increased num-
ber of osteoblasts, have no differences in the frequency or ab-
solute number of HSCs, common lymphoid progenitors, com-
mon myeloid/megakaryocyte erythroid progenitors, or granu-
locyte/monocyte progenitors, confirming the findings in mice 
overexpressing the constitutive PTH/PTHrP receptor in osteo-
cytes [44]. Interestingly, in these mice, B cells are significantly 
reduced in both their frequency and cell number in the bone 
marrow and the reduction was a consequence of increased 
apoptosis due to a reduction in Cxcl12 expression in the stro-
mal cells.
FUTURE DIRECTIONS
It is evident that there is a need for further investigations 
aimed at better understand osteocytes function. Several ques-
tion remain unanswered and areas in need of better under-
standing are numerous. For example, which are the molecular 
cues that signal an osteoblast to become an osteocyte? How 
can osteocytes sense mechanical forces applied to the skeleton 
and what is the role of primary cilia? What control the in-
creased in SOST/sclerostin induced by unloading? How can 
an osteocyte sense phosphate? What is the role of osteocytes 
in hematopoiesis? These are many more other unanswered 
questions will require better tools and in vitro models to study 
and analyze these cells and advance our understanding of their 
complex functions even further.
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